# Invetx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/invetx

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.invetx.com
- Total disclosed funding: $81M
- Latest round: Series B (Mar 29, 2022)
- Investors on record: 9

## About

Invetx, Inc., located in Boston, US, specializes in biotechnology innovations for pet health, focusing on developing biopharmaceutical products that treat chronic conditions in dogs and cats.Founded in 2018 in Boston, US, Invetx, Inc. is engaged in the development of biopharmaceutical solutions for pets. The company is led by CEO Juergen Horn, who has a background in founding other ventures. The company has raised a total of USD 55.50 mn through various funding rounds, with the most recent being an Add-on Trade Sale on July 18, 2024, where Dechra Pharmaceuticals PLC agreed to acquire Invetx for USD 520 mn.Invetx focuses on developing biopharmaceutical products that cater to the health of dogs and cats, specifically targeting chronic conditions such as osteoarthritis, allergies, cancer, and diabetes. They have developed a Half-Life Extension Technology Platform, aimed at prolonging the efficacy of monoclonal antibody treatments, thereby enhancing veterinary care. Their products, which are primarily offered in the United States, are informed by market research indicating a high prevalence of chronic conditions among dogs, emphasizing the need for specialized treatments.Invetx generates revenue through direct sales to veterinary clinics and strategic partnerships with animal hospitals and pet owners. The company has successfully completed an oversubscribed Series B financing round amounting to USD 60.50 mn, showcasing investor trust in their innovative pipeline. Their product line includes IVX-01, a novel monoclonal antibody, and they collaborate with industry leaders like Boehringer Ingelheim to broaden their market reach.Following the recent acquisition agreement with Dechra Pharmaceuticals PLC, effective July 2024, Invetx will leverage this partnership to enhance its offerings in drug treatments and compliance services for pets. The acquisition will facilitate the development and launch of new products aimed at addressing unmet needs in veterinary medicine. Additionally, Invetx plans to expand its market presence internationally, targeting regions with growing demands for veterinary biotherapeutics. This funding and strategic partnership will support their ongoing growth initiatives.

## Funding rounds

- Series B, Mar 29, 2022, $56M — Novo Holdings, Eight Roads Ventures, Tekla Capital Management, F-Prime Capital, GV, Casdin Capital, Anterra Capital
- Series A, Sep 30, 2020, $10M — Tekla Capital Management, Casdin Capital, Anterra Capital, AbCellera Biologics Inc., WuXi Biologics (Cayman) Inc.
- Series A, Feb 21, 2020, $15M — Anterra Capital, AbCellera Biologics Inc., WuXi Biologics (Cayman) Inc.

## Investors

- Anterra Capital (https://capitalatlas.ai/funds/anterra-capital) — Series A, Series B
- AbCellera Biologics Inc. — Series A
- WuXi Biologics (Cayman) Inc. — Series A
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A, Series B
- Novo Holdings — Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B